Non-Invasive Tests of Non-Alcoholic Fatty Liver Disease: Perspective Review

Le résumé fourni par la source

Cirrhosis and hepatocellular carcinoma often develop from Non-Alcoholic Fatty Liver Disease (NAFLD), a progressive condition characterized by hepatic steatosis, inflammation and varying degrees of fibrosis. The increasing incidence of non-alcoholic steatohepatitis (NASH) highlights the need for effective diagnostic and treatment methods. Non-invasive tests (NITs) have emerged as promising tools for evaluating and monitoring NAFLD, offering safer and more cost-effective alternatives to invasive liver biopsies. This review focuses on the current state of NITs in NAFLD management, emphasizing their diagnostic accuracy, prognostic significance, and role in guiding treatment. NITs discussed include transient elastography, magnetic resonance imaging (MRI), magnetic resonance elastography (MRE) and serum biomarker panels such as the NAFLD fibrosis score, Fibro Test, and Enhanced Liver Fibrosis (ELF) test. Recent advancements in MRI and MRE have greatly improved the non-invasive assessment of liver fibrosis and steatosis, enhancing sensitivity and specificity for early detection and risk stratification. Additionally, combined serum biomarker panels have shown promise in predicting disease severity and progression, aiding in the identification of high-risk patients who could benefit from early intervention. By enabling prompt diagnosis, comprehensive risk assessment and monitoring of disease progression, the integration of NITs into standard clinical practice offers significant potential for improving NAFLD management. Ongoing research efforts are focused on developing new NITs and optimizing existing methods to enhance diagnostic precision and prognostic evaluation in NAFLD patients. This evolving landscape of non-invasive assessment tools could revolutionize the approach to managing this increasingly prevalent liver disease. Keywords: Fatty liver, Liver biopsy, Transient Elastography, Serum biomarkers, Hepatic Cell Carcinoma.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.